Intensity Modulated Radiation Therapy - Prostate Cancer

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Sep 12, 2005

Keywords

ClinConnect Summary

No description provided

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Histologic diagnosis of adenocarcinoma of the prostate within six months of entry
• • Clinical stage T1B, T1C, T2A-C NX MO (see Appendix 1 for staging). Any Gleason score is eligible for entry, but Gleason score must be determined.
• • Patients with a PSA \>10.0 and Gleason score of 7; or patients with any PSA value and Gleason score of \>8 must have clinically negative lymph nodes as determined by a pelvic CT scan done within 12 weeks of entry. A negative bone scan is required before entry for all patients with Gleason score \>8, or any patient with a Gleason score of 7, and a PSA \>10.
• • The patient must not have received any cytotoxic anticancer therapy. Previous or concurrent hormonal therapy for local disease is acceptable.
• • ECOG performance status of 1 or less
• • Age 80 years old or less
• • Serum PSA \<25 ng/ml within 4 weeks of study entry
• • Informed consent
• Exclusion Criteria:
• • Patients with history of inflammatory bowel disease or other contraindication to radical radiation therapy
• • Patients with prior colorectal surgery
• • Any prior pelvic radiotherapy. Any prior TURP done \<12 weeks from study entry.
• • Any previous cytotoxic chemotherapy
• • Patients with prior malignancy except non-melanoma skin carcinoma within 5 years of the diagnosis of prostate cancer